ARS Pharmaceuticals, Inc.

SPRY · Nasdaq · United States

Share price · SPRY

$3.69-2.61 (-41.43%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.7M (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when SPRY's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+10.6%

    Nothing announced by SPRY that day or the session before.

  2. 10 Nov 2026+13.3%

    Nothing announced by SPRY that day or the session before.

  3. 9 Nov 2026+12.9%

    Nothing announced by SPRY that day or the session before.

  4. 9 Oct 2026-7.2%

    Nothing announced by SPRY that day or the session before.

  5. 25 Jun 2026-23.9%
  6. 28 May 2026+10.6%

    Nothing announced by SPRY that day or the session before.

  7. 13 May 2026-7.2%
  8. 22 Apr 2026+7.1%

    Nothing announced by SPRY that day or the session before.

  9. 26 Mar 2026+8.4%

    Nothing announced by SPRY that day or the session before.

  10. 12 Jan 2026-12.9%

    Nothing announced by SPRY that day or the session before.

Share of unusual movement by asset

For each asset, the share of SPRY's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Alpha- and beta-adrenergic receptors (agonist)Small molecule
Allergic Conditions
Anaphylaxis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Epinephrine · neffyPhase 2Urticaria Chronic
Est. primary completion 2027-06 · NCT06927999 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$38M$18M$26M+ $113M short-term inv.$36M-$34M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$34M$4.7M$8.2M+ $136M short-term inv.$62M-$61M operating cash flowreport ↗
2026-Q1$23M$4.3M$24M+ $177M short-term inv.$61M-$45M operating cash flowreport ↗
2025-Q3$33M$2.8M$60M+ $229M short-term inv.$51M-$47M operating cash flowreport ↗
2025-Q2$16M$4.0M$52M+ $189M short-term inv.$45M-$40M operating cash flowreport ↗
2025-Q1$8.0M$3.0M$40M+ $236M short-term inv.$34M-$41M operating cash flowreport ↗
2024-Q3$2.1M$4.4M$40M+ $165M short-term inv.$19M-$14M operating cash flowreport ↗
2024-Q2$0.5M$6.9M$37M+ $182M short-term inv.$13M-$7.3M operating cash flowreport ↗
2024-Q1$0$5.2M$56M+ $168M short-term inv.$10M-$6.7M operating cash flowreport ↗
2023-Q3$0$3.0M$61M+ $181M short-term inv.$15M-$13M operating cash flowreport ↗
2023-Q2<$0.1M$7.3M$119M+ $133M short-term inv.$17M-$17M operating cash flowreport ↗
2023-Q1<$0.1M$6.5M$88M+ $177M short-term inv.$15M-$12M operating cash flowreport ↗
2022-Q3$0.2M$8.4M$203M+ $63M short-term inv.$18M-$17M operating cash flowreport ↗
2022-Q2$0.5M$12M$219M+ $39M short-term inv.$19M-$15M operating cash flowreport ↗
2022-Q1$0.7M$17M$234M+ $20M short-term inv.$25M-$20M operating cash flowreport ↗
2021-Q3—$16M$301M$23M-$19M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$84M$13M$41M+ $204M short-term inv.$43M-$171M operating cash flowreport ↗

ARS Pharmaceuticals reported full-year 2025 total revenue of $84.28M, down 5.5% YoY, composed of $72.2M in U.S. neffy net product revenue, $9.7M in collaboration revenue, and $2.4M in supply revenue. R&D spend was $13.18M, down 32.7% YoY. Cash and equivalents were $41.32M, while total cash, cash equivalents, and short-term investments were $245.0M at year-end. The company reported a net loss of $171.3M, or $1.74 per share, and a quarterly net burn of $171.3M.

Management stated that the year-end cash position is expected to fund operations through anticipated cash-flow break-even, with similar annualized promotional investment planned for 2026. Commercial highlights included more than 22,500 prescribing healthcare providers, over 9,000 schools in the neffy inSchools program, about 10% of neffy prescription volume facilitated through getneffy.com, and a planned sales force expansion from 106 to 150 representatives beginning in the second quarter of 2026. Regulatory and clinical developments included neffy approvals in China and Australia in December 2025, a positive CHMP opinion for EUR neffy 1 mg in January 2026, an expected Canadian approval in the second quarter of 2026, and an ongoing Phase 2b trial in chronic spontaneous urticaria with interim data anticipated in the second half of 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$89M$20M$51M+ $263M short-term inv.—$14M operating cash flowreport ↗
2023-FY<$0.1M$20M$71M+ $157M short-term inv.$14M-$59M operating cash flowreport ↗
2022-FY$1.3M$18M$211M+ $64M short-term inv.$8.7M-$40M operating cash flowreport ↗
2021-FY$5.5M$62M$254M+ $0 short-term inv.$22M-$67M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($284K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-02Slebir John L · Chief Legal OfficerAward / grant (derivative)1,199,482——Form 4
2026-10-01Casale Donn · director, President and CEOAward / grant (derivative)1,036,923——Form 4
2026-09-01Smith Margaret Ekins · Chief Commercial OfficerAward / grant (derivative)1,001,738——Form 4
2026-07-01Casale Donn · PresidentAward / grant (derivative)898,456——Form 4
2026-06-24Shawver Laura · directorAward / grant (derivative)30,000——Form 4
2026-06-24SCHNEIDER PHILLIP M · directorAward / grant (derivative)30,000——Form 4
2026-06-24SAUNDERS BRENT L · directorAward / grant (derivative)30,000——Form 4
2026-06-24Thompson Peter A. · directorAward / grant (derivative)30,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 201 reporting institutions held 93.3M shares ($732.9M, 93.8% of shares outstanding).

#InstitutionSharesValue
1RA CAPITAL MANAGEMENT, L.P.10,860,977$87.2M
2ORBIMED ADVISORS LLC8,288,510$66.6M
3Rubric Capital Management LP8,000,000$64.2M
4DEERFIELD MANAGEMENT COMPANY, L.P.7,503,812$60.3M
5MILLENNIUM MANAGEMENT LLC5,982,919$48.0M
6BlackRock, Inc.5,012,254$40.2M
7Aberdeen Group plc4,113,617$33.0M
8SR One Capital Management, LP4,012,903$32.2M
9STATE STREET CORP3,644,966$29.3M
10FRANKLIN RESOURCES INC3,278,549$26.3M
11Tyro Capital Management LLC2,968,599$23.8M
12VANGUARD CAPITAL MANAGEMENT LLC2,542,504$20.4M
13UBS Group AG2,260,325$18.2M
14CITADEL ADVISORS LLC1,773,188$14.2M
15GEODE CAPITAL MANAGEMENT, LLC1,526,824$12.3M